Publication | Closed Access

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

Breast OncologyOncologyMetastatic SettingsMedicineImmunologyPathologyBreast CancerCancer TreatmentCancer GeneticsMolecular DiagnosticsMolecular OncologyHer2-positive Breast Cancer